NDAORALCAPSULE
Approved
May 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
15
Clinical Trials (5)
A Ph 1 Study of Epanova® in Healthy Chineses
Started Jun 2018
14 enrolled
Healthy Subjects
A Double-blind Randomized Placebo-controlled Study Comparing Epanova and Fenofibrate on Liver Fat in Overweight Subjects.
Started Sep 2015
78 enrolled
Non-alcoholic Fatty Liver Disease (NAFLDHypertriglyceridemia
A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI
Started Mar 2015
490 enrolled
Diabetes Mellitus, Type 2Exocrine Pancreatic Insufficiency
Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions
Started Feb 2015
137 enrolled
Relative BioavailabilityAUCCmax+1 more
Outcomes Study to Assess STatin Residual Risk Reduction With EpaNova in HiGh CV Risk PatienTs With Hypertriglyceridemia
Started Oct 2014
13,078 enrolled
Eligible Men or Women Considered High Risk for Atherosclerotic Cardiovascular Disease (CVD)
Loss of Exclusivity
LOE Date
Jan 4, 2033
83 months away
Patent Expiry
Jan 4, 2033
External Resources